RESULTS AND COMMENTS ON ADVANCE STUDY
https://doi.org/10.20996/1819-6446-2007-3-4-104-109
Abstract
Results and comments on ADVANCE study.
References
1. Dahlof B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
2. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-258.
3. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-1535.
4. Collins R., Peto R., MacMahon S., et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-838.
5. Dagenais G.R., Pogue J., Fox K., et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction of heart failure: a combined analysis of three trials. Lancet 2006;368:581-588.
6. Danchin N., Cucherat M., Thuillez C., et al. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction. Arch Intern Med 2006;166:787-796.
7. Strippoli G.F.M., Craig M.C., Schena F.P., Craig J.C. Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression. J Am Soc Nephrol 2006;17:S153-155.
8. Anavekar N.S., McMurray J.J., Velazquez E.J., et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285-1295. 9. Go A.S., Chertow G.M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
9. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317: 703- 713.
10. Stolk R.P., Vingerling J.R., Cruickshank J.K., et al. Rationale and design of the AdRem study: Evaluating the effects of blood pressure lowering and intensive glucose control on vascular retinal disorders in patients with type 2 diabetes mellitus. Contemp Clin Trials 2007; 28: 6-17.
Review
For citations:
Gilyarevsky S.R. RESULTS AND COMMENTS ON ADVANCE STUDY. Rational Pharmacotherapy in Cardiology. 2007;3(4):104-109. (In Russ.) https://doi.org/10.20996/1819-6446-2007-3-4-104-109
Views:
2348
Email this article 